OPKO Health's Global Products growth, partnered therapies and advancing pipeline support its outlook, but clinical risks and market headwinds pose challenges.
OPKO Health NASDAQ: OPK reported 16% growth in third-quarter revenue from continuing operations and outlined plans to focus on drug development and pharmaceutical products following its proposed sale of BioReference assets to Labcorp.
OPKO Health (OPK) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.03 per share a year ago.
MIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended September 30, 2026. Third Quarter 2026 and Recent Business Highlights OPKO enters into agreement with Labcorp for the sale of substantially all remaining BioReference diagnostic operations.
MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026 on Wednesday, November 4, 2026. OPKO's senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance.
KIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ: OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial of OPK-8801001, an investigational, long acting human growth hormone receptor antagonist being developed for the treatment of acromegaly.
OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Kscore Test.
Labcorp Holdings Inc. (NYSE:LH) stock traded higher Thursday after the company agreed to acquire select assets of BioReference Health from OPKO Health Inc. (NASDAQ:OPK) in a deal worth up to $872 million.
Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla.